RSNA 2016

Abstract Archives of the RSNA, 2016


MS150-ED-TUA2

Checking In with Checkpoint Inhibition: Imaging Review of PD1 Inhibitor Immune-Related Adverse Events

Tuesday, Nov. 29 12:15PM - 12:45PM Room: MS Community, Learning Center Station #2



FDA Discussions may include off-label uses.

Awards
Certificate of Merit

Matthew Quirk, MD, Los Angeles, CA (Presenter) Nothing to Disclose
Antonio J. Gutierrez, MD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Kathleen Ruchalski, MD, Santa Monica, CA (Abstract Co-Author) Nothing to Disclose
Robert D. Suh, MD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Dean Wallace, MD, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Pawan Gupta, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
Antoni Ribas, Los Angeles, CA (Abstract Co-Author) Nothing to Disclose
TEACHING POINTS

1. Discuss the novel role of programmed cell death 1 (PD1) inhibitors in current cancer therapy, and understand their pharmacologic mechanisms.
2. Recognize the imaging manifestations of PD1 inhibitor immune-related adverse events across a variety of organ systems.
3. Case-based approach to PD1 inhibitor immune-related imaging findings.

TABLE OF CONTENTS/OUTLINE

PD1 inhibition – novel role in cancer therapy Pharmacologic mechanisms of PD1 inhibition FDA-approved use in cancer subtypes and emerging applications Immune-related adverse events and their treatmentImaging manifestations of PD1 inhibitor immune-related adverse events Hypophysitis – enlargement and abnormal MRI signal with clinical hypopituitarism Thyroiditis – heterogeneous enhancement and atrophy with clinical hypothyroidism Organizing Pneumonia – airspace consolidations and ground-glass attenuation ARDS – diffuse ground-glass attenuation and consolidations Pleuritis – progressive diffuse pleural thickening with pathologic correlation       Pancreatitis – diffuse hypermetabolism on FDG PET/CT Nephritis – geographic hypoenhancing renal lesions Mesenteritis – soft tissue masses, lymphadenopathy and fat stranding with pathologic correlation Colitis – colonic wall thickening and fat strandingConclusion Consider immune-related adverse events in patients on PD1 therapy